Gene Abnormalities and Modulated Gene Expression Associated with Radionuclide Treatment: Towards Predictive Biomarkers of Response

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl adolyguadolygiad gan gymheiriaid

Fersiynau electronig

Dangosydd eitem ddigidol (DOI)

Molecular radiotherapy (MRT), also known as radioimmunotherapy or targeted radiotherapy, is the delivery of radionuclides to tumours by targeting receptors overexpressed on the cancer cell. Currently it is used in the treatment of a few cancer types including lymphoma, neuroendocrine, and prostate cancer. Recently reported outcomes demonstrating improvements in patient survival have led to an upsurge in interest in MRT particularly for the treatment of prostate cancer. Unfortunately, between 30% and 40% of patients do not respond. Further normal tissue exposure, especially kidney and salivary gland due to receptor expression, result in toxicity, including dry mouth. Predictive biomarkers to select patients who will benefit from MRT are crucial. Whilst pre-treatment imaging with imaging versions of the therapeutic agents is useful in demonstrating tumour binding and potentially organ toxicity, they do not necessarily predict patient benefit, which is dependent on tumour radiosensitivity. Transcript-based biomarkers have proven useful in tailoring external beam radiotherapy and adjuvant treatment. However, few studies have attempted to derive signatures for MRT response prediction. Here, transcriptomic studies that have identified genes associated with clinical radionuclide exposure have been reviewed. These studies will provide potential features for seeding multi-component biomarkers of MRT response.

Allweddeiriau

Iaith wreiddiolSaesneg
Rhif yr erthygl15060688
Tudalennau (o-i)688
Nifer y tudalennau16
CyfnodolynGenes
Cyfrol15
Rhif y cyfnodolyn6
Dyddiad ar-lein cynnar26 Mai 2024
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - 26 Mai 2024
Gweld graff cysylltiadau